Literature DB >> 19254701

Neuropeptide Y modulates the antidepressant activity of imipramine in olfactory bulbectomized rats: involvement of NPY Y1 receptors.

Sameer N Goyal1, Manoj A Upadhya, Dadasaheb M Kokare, Snehal M Bhisikar, Nishikant K Subhedar.   

Abstract

Since long-term treatment with imipramine increases the neuropeptide Y (NPY) levels in the frontal cortex and hypothalamus, the possibility exists that the antidepressant action of imipramine may be mediated via the NPY Y1 receptors. Bilateral olfactory bulbectomy (OBX) resulted in hyperactivity (increased number of ambulation, rearing and grooming episodes) in open field test (OFT) suggesting a depression-like condition. Chronic (14 days) administration of NPY, NPY Y1/Y5 receptor agonist [Leu(31), Pro(34)]-NPY (intracerebroventricular, i.c.v.) or tricyclic antidepressant imipramine (intraperitoneal) to OBX rats dose-dependently resulted in decreased hyperactivity in OFT, while selective NPY Y1 receptor antagonist BIBP3226 (i.c.v.) produced opposite effects. The antidepressant actions of imipramine were enhanced by co-administration of NPY or [Leu(31), Pro(34)]-NPY, and antagonized by BIBP3226 given at sub-effective doses. The data suggest that NPY, acting via NPY Y1 receptors, may be involved in antidepressant action of imipramine in OBX rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254701     DOI: 10.1016/j.brainres.2009.02.033

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder.

Authors:  Hagit Cohen; Tianmin Liu; Nitsan Kozlovsky; Zeev Kaplan; Joseph Zohar; Aleksander A Mathé
Journal:  Neuropsychopharmacology       Date:  2011-10-05       Impact factor: 7.853

2.  Neuropeptide Y protects rat cortical neurons against β-amyloid toxicity and re-establishes synthesis and release of nerve growth factor.

Authors:  Nicoletta Croce; Maria Teresa Ciotti; Francesca Gelfo; Silvia Cortelli; Giorgio Federici; Carlo Caltagirone; Sergio Bernardini; Francesco Angelucci
Journal:  ACS Chem Neurosci       Date:  2012-01-30       Impact factor: 4.418

3.  Environmental Enrichment Reduces Anxiety by Differentially Activating Serotonergic and Neuropeptide Y (NPY)-Ergic System in Indian Field Mouse (Mus booduga): An Animal Model of Post-Traumatic Stress Disorder.

Authors:  Durairaj Ragu Varman; Koilmani Emmanuvel Rajan
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

4.  Targeting the Neuropeptide Y System in Stress-related Psychiatric Disorders.

Authors:  Nicole M Enman; Esther L Sabban; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Neurobiol Stress       Date:  2015-01-01

Review 5.  Neuropeptide Y in Alcohol Addiction and Affective Disorders.

Authors:  Annika Thorsell; Aleksander A Mathé
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-31       Impact factor: 5.555

6.  NPY1 Receptor Agonist Modulates Development of Depressive-Like Behavior and Gene Expression in Hypothalamus in SPS Rodent PTSD Model.

Authors:  Lidia Serova; Hannah Mulhall; Esther Sabban
Journal:  Front Neurosci       Date:  2017-04-19       Impact factor: 4.677

7.  Maternal Deprivation Increases Anxiety- and Depressive-Like Behaviors in an Age-Dependent Fashion and Reduces Neuropeptide Y Expression in the Amygdala and Hippocampus of Male and Female Young Adult Rats.

Authors:  Alexandra S Miragaia; Guilherme S de Oliveira Wertheimer; Amanda C Consoli; Rafael Cabbia; Beatriz M Longo; Carlos E N Girardi; Deborah Suchecki
Journal:  Front Behav Neurosci       Date:  2018-08-07       Impact factor: 3.558

8.  NPY Receptor 2 Mediates NPY Antidepressant Effect in the mPFC of LPS Rat by Suppressing NLRP3 Signaling Pathway.

Authors:  Wenjiao Wang; Tao Xu; Xinyue Chen; Kemeng Dong; Chunkai Du; Jing Sun; Cuige Shi; Xiaoxiao Li; Yutao Yang; Hui Li; Zhi-Qing David Xu
Journal:  Mediators Inflamm       Date:  2019-05-15       Impact factor: 4.711

Review 9.  Update on GPCR-based targets for the development of novel antidepressants.

Authors:  Ioannis Mantas; Marcus Saarinen; Zhi-Qing David Xu; Per Svenningsson
Journal:  Mol Psychiatry       Date:  2021-02-15       Impact factor: 15.992

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.